Review on combination strategy of immune checkpoint blockade, photodynamic therapy and nanomedicine against solid tumor

Xin Li,Yu Zhen,Shanshan Li

DOI: https://doi.org/10.1016/j.matdes.2021.109958

2021-11-01

Abstract:<p>Over the past decades, increasing numbers of novel treatments of solid tumors have been approved and displayed great clinical efficacy, such as immune checkpoint blockade (ICB), photodynamic therapy (PDT) and advanced nanomedicine strategy. Although deficient targeting ability and extensive toxic side effect limit the monotherapy of these treatments in clinic, combination of them can offset the defects of each other and complementarily and synergistically elicit antitumor effects as evidenced by pre-clinical and clinical trials. Herein, we summarize the status of ICB, PDT and nanotechnology in current tumor therapy, and focus on the advances of combination of the three platforms in preclinical models and discuss their future directions and clinical application.</p>

materials science, multidisciplinary

What problem does this paper attempt to address?

The main problem this paper attempts to address is how to improve the therapeutic efficacy against solid tumors through a combined strategy of immune checkpoint blockade (ICB), photodynamic therapy (PDT), and nanomedicine. Specifically, the paper explores the following points:

1. **Immune Checkpoint Blockade (ICB)**: ICB is a promising cancer immunotherapy that activates the host's anti-tumor response by using immune checkpoint inhibitors. However, when used alone, ICB faces issues such as insufficient targeting ability, limited benefit rate, and high systemic toxic side effects.

2. **Photodynamic Therapy (PDT)**: PDT is a modern non-invasive treatment method that generates reactive oxygen species (ROS) under appropriate wavelength light exposure through the local or systemic application of photosensitizers (PS), thereby producing selective cytotoxic effects on malignant cells. However, the effectiveness of PDT is limited by factors such as poor solubility of photosensitizers, self-quenching, and poor biodistribution.

3. **Nanomedicine**: Nanomaterials, with their appropriate pore size, flexible structure, good biocompatibility, and other unique properties, can serve as drug delivery systems to improve the targeting ability and biodistribution of photosensitizers and immune checkpoint inhibitors, reducing toxic side effects.

The main purpose of the paper is to summarize the current application status of ICB, PDT, and nanotechnology in tumor treatment, with a focus on the latest progress in the combined use of these three platforms, particularly the synergistic effects in animal models, as well as future research directions and clinical application prospects. Through this combined strategy, the shortcomings of single therapies can be overcome, complementing and synergistically exerting anti-tumor effects.